[{"id":"1e3be90b-cc8d-4ccf-9c21-3f3fb2a8ae0a","acronym":"SEACLIFF","url":"https://clinicaltrials.gov/study/NCT07181161","created_at":"2025-09-20T07:05:48.306Z","updated_at":"2025-09-20T07:05:48.306Z","phase":"Phase 1/2","brief_title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT07181161 - SEACLIFF","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD9574"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 09/22/2025","start_date":" 09/22/2025","primary_txt":" Primary completion: 01/09/2029","primary_completion_date":" 01/09/2029","study_txt":" Completion: 01/09/2029","study_completion_date":" 01/09/2029","last_update_posted":"2025-09-18"},{"id":"3a8e94f4-0040-4f56-93f4-fd86db056dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06879041","created_at":"2025-06-07T14:42:17.891Z","updated_at":"2025-06-07T14:42:17.891Z","phase":"Phase 1","brief_title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06879041","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/10/2025","start_date":" 03/10/2025","primary_txt":" Primary completion: 04/16/2029","primary_completion_date":" 04/16/2029","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2025-06-04"},{"id":"58481425-6a53-4802-b306-7ed470c87380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221542","created_at":"2021-01-18T20:32:52.184Z","updated_at":"2025-02-25T16:52:48.663Z","phase":"Phase 1","brief_title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04221542","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2025-02-04"},{"id":"00e8ec23-03be-49d1-9f43-a54b7be00360","acronym":"","url":"https://clinicaltrials.gov/study/NCT06555796","created_at":"2025-02-25T17:03:57.511Z","updated_at":"2025-02-25T17:03:57.511Z","phase":"Phase 1","brief_title":"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer","source_id_and_acronym":"NCT06555796","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2024","start_date":" 09/23/2024","primary_txt":" Primary completion: 09/22/2026","primary_completion_date":" 09/22/2026","study_txt":" Completion: 03/23/2029","study_completion_date":" 03/23/2029","last_update_posted":"2025-02-03"},{"id":"68cc78ab-dc4e-4e90-9e23-e14c4cde86a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06613100","created_at":"2025-02-26T09:23:12.905Z","updated_at":"2025-02-26T09:23:12.905Z","phase":"Phase 1","brief_title":"Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer","source_id_and_acronym":"NCT06613100","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/21/2026","primary_completion_date":" 06/21/2026","study_txt":" Completion: 10/25/2029","study_completion_date":" 10/25/2029","last_update_posted":"2024-12-16"},{"id":"e5a1e1ed-835e-42f6-b648-d803c13e2542","acronym":"","url":"https://clinicaltrials.gov/study/NCT01774071","created_at":"2021-01-18T07:49:16.883Z","updated_at":"2024-07-02T16:35:49.015Z","phase":"Phase 1/2","brief_title":"Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer","source_id_and_acronym":"NCT01774071","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vandortuzumab vedotin (RG7450)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/02/2023","primary_completion_date":" 05/02/2023","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-05-04"},{"id":"f1c79968-d356-41b7-bc91-2e25cb1eaa01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05428319","created_at":"2022-06-23T16:59:03.338Z","updated_at":"2024-07-02T16:36:04.291Z","phase":"","brief_title":"Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers","source_id_and_acronym":"NCT05428319","lead_sponsor":"Sohag University","biomarkers":" STEAP1","pipe":" | ","alterations":" STEAP1 expression","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STEAP1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-08"}]